People: argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

13 Dec 2019
Change (% chg)

$1.17 (+0.75%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Leupin, Nicolas 

Dr. Nicolas Leupin has served as Chief Medical Officer of argenx SE since February 1, 2016. Dr. Leupin has clinical and industry expertise in medical oncology as well as experience in drug development. He currently lectures at the University of Bern. From 2008 to 2015, Dr. Leupin served in different positions in clinical development at Celgene, including Director of Clinical Development of EMEA Celgene, where he contributed to building the clinical development department in Europe and then led the European lymphoma and myeloma teams, served as clinical lead for several compounds up to phase III clinical trials, and was responsible for running and managing hematology and oncology clinical trials, including both industry-sponsored trials and academic cooperative groups, several of them through to registration. Among other activities, he was responsible for specific clinical documents of registration dossiers that lead to European and American registrations. Dr. Leupin holds an MBA from Jones International University and an M. D. from Bern University in Switzerland and was board certified in medical oncology (Switzerland).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --